1. Home
  2. BCAX
  3. BCAX News

Latest BICARA THERAPEUTICS INC (BCAX) News on May 10, 2025

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
BCAX

GlobeNewswire

12 days ago

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

BCAX

MT Newswires

12 days ago

Wedbush Trims Price Target on Bicara Therapeutics to $30 From $31, Keeps Outperform Rating

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
BCAX

GlobeNewswire

17 days ago

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

BCAX

MT Newswires

23 days ago

Wells Fargo Initiates Bicara Therapeutics at Underweight With $8 Price Target

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
BCAX

GlobeNewswire

a month ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
BCAX

GlobeNewswire

a month ago

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth
BCAX

Simply Wall St.

2 months ago

Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
BCAX

GlobeNewswire

3 months ago

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
BCAX

GlobeNewswire

3 months ago

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

BCAX

MT Newswires

3 months ago

Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
BCAX

GlobeNewswire

3 months ago

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia
BCAX

Clinical Trials Arena

4 months ago

Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia

BCAX

MT Newswires

6 months ago

Bicara Therapeutics' Q3 Loss Narrows

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
BCAX

GlobeNewswire

6 months ago

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
BCAX

GlobeNewswire

6 months ago

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Opening Day: Another trio of biotech IPOs make Friday debut
BCAX

TipRanks

7 months ago

Opening Day: Another trio of biotech IPOs make Friday debut

BCAX

Investing.com

7 months ago

MBX Biosciences earns Buy rating at three investment firms

BCAX

GuruFocus.com

8 months ago

RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares

TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc
BCAX

GuruFocus.com

8 months ago

TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc

FMR LLC Acquires New Stake in Bicara Therapeutics Inc
BCAX

GuruFocus.com

8 months ago

FMR LLC Acquires New Stake in Bicara Therapeutics Inc

BCAX

MT Newswires

8 months ago

Bicara Therapeutics Insider Bought Shares Worth $1,260,000, According to a Recent SEC Filing

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity
BCAX

Pharmaceutical Technology

8 months ago

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity

BCAX

MT Newswires

8 months ago

MBX Biosciences Closes Upsized IPO

BCAX

MT Newswires

8 months ago

Bicara Therapeutics Closes $362 Million IPO

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
BCAX

GlobeNewswire

8 months ago

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Share on Social Networks: